Optovue, the global leader in the development of optical coherence tomography (OCT) and OCT angiography (OCTA), today announced immediate availability of AngioVue™ Retina, a proprietary imaging system that provides retina specialists with a non-invasive, dyeless way to quickly visualize blood flow in the retina, the light sensitive portion in the back of the eye.
AngioVue Retina is configured with essential OCTA and OCT features designed specifically for retinal practices to allow adoption of OCT and OCTA into the clinical workflow with minimal disruption.
“By adding AngioVue Retina to our product portfolio, we are able to help retinal physicians acquire OCTA technology in a cost-efficient manner thereby adding this technology to their armamentarium of diagnostic imaging tools,” said John Hawley, senior vice president of Global Sales for Optovue. “OCTA imaging is in its nascent phase and we expect applications to rapidly unfold over the next few years. As such, we are pleased to offer this important technology in different product configurations that meet the needs of all ophthalmology practices.”
Optovue’s AngioVue Retina provides retinal specialists with the ability to quickly visualize the presence or absence of retinal vessels and assess new information about the microvasculature with extraordinary detail. This information may be integrated with other diagnostic imaging results to form a complete picture of a patient’s disease state and their treatment options.
The company also announced its new DualTrac Motion Correction for use with both the AngioVue and AngioVue Retina systems, a two-level approach to correcting motion artifacts resulting from patient movement. The first level provides real-time correction for rapid eye movements, blinking or eye drifting. The second level occurs during imaging post-processing and corrects smaller levels of motion distortion. This combined approach results in robust motion correction for patients who have trouble directing their focus on a central point during an eye exam, which is essential for high quality OCTA imaging.
Optovue recently received FDA clearance for its AngioVue Imaging System, bringing the significant benefits of non-invasive retinal imaging to patients in the U.S. who suffer from diseases that lead to progressive blindness. In addition to retina applications, the AngioVue System is a comprehensive platform that addresses other ophthalmology applications such as imaging the front of the eye and the optic nerve. The AngioVue System first received regulatory clearance for use outside the US in 2014.
Optovue is the first company to develop and commercialize the pioneering OCTA technology. Utilizing light rays to form detailed three-dimensional images of the retina, physicians are able to quickly visualize the blood vessels. In less than three seconds, the AngioVue System acquires a single image that complements the current angiography imaging standard, fluorescein angiography (FA), but with a number of advantages. Unlike FA, the AngioVue System does not require the use of dye injections, which can often obscure the target anatomy and can lead to side effects and other complications associated with dye-based, invasive procedures.
Optovue, Inc. is a privately held medical device company founded in 2003. Headquartered in Fremont, Calif., the company is dedicated to the advancement and commercialization of high-speed OCT and OCTA technology used to facilitate the diagnosis and management of eye diseases, many of which may lead to permanent blindness. To date, there are over 100 peer-reviewed publications detailing the AngioVue Imaging System technology and clinical applications. Optovue has installed over 10,000 products worldwide and employs over 170 people. For more information, visit www.optovue.com.